Jamie Christensen Sells 14,725 Shares of Mirati Therapeutics, Inc. (MRTX) Stock

Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 14,725 shares of the company’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $22.99, for a total transaction of $338,527.75. Following the completion of the sale, the senior vice president now owns 6,395 shares of the company’s stock, valued at approximately $147,021.05. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Jamie Christensen also recently made the following trade(s):

  • On Thursday, November 16th, Jamie Christensen sold 10,275 shares of Mirati Therapeutics stock. The shares were sold at an average price of $18.00, for a total transaction of $184,950.00.
  • On Thursday, November 2nd, Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock. The shares were sold at an average price of $14.00, for a total transaction of $104,986.00.

Shares of Mirati Therapeutics, Inc. (MRTX) traded up $1.45 during midday trading on Thursday, reaching $23.20. 804,550 shares of the company were exchanged, compared to its average volume of 387,470. The firm has a market cap of $587.11, a price-to-earnings ratio of -7.46 and a beta of 1.79. Mirati Therapeutics, Inc. has a 12-month low of $2.70 and a 12-month high of $23.45.

Mirati Therapeutics (NASDAQ:MRTX) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.16. research analysts anticipate that Mirati Therapeutics, Inc. will post -2.73 earnings per share for the current year.

MRTX has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. HC Wainwright restated a “buy” rating on shares of Mirati Therapeutics in a research report on Tuesday, November 7th. ValuEngine upgraded shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 15th. Leerink Swann upgraded shares of Mirati Therapeutics from a “market perform” rating to an “outperform” rating and set a $9.00 price objective for the company in a research report on Tuesday, November 14th. Finally, Oppenheimer initiated coverage on shares of Mirati Therapeutics in a research report on Monday, September 18th. They issued an “outperform” rating and a $18.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Mirati Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $14.75.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Broadfin Capital LLC boosted its stake in Mirati Therapeutics by 19.1% in the 2nd quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock worth $9,091,000 after purchasing an additional 400,000 shares during the period. Dimensional Fund Advisors LP boosted its stake in Mirati Therapeutics by 53.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 199,563 shares of the biotechnology company’s stock worth $728,000 after purchasing an additional 69,377 shares during the period. Citadel Advisors LLC acquired a new position in Mirati Therapeutics in the 3rd quarter worth $268,000. Jane Street Group LLC acquired a new position in Mirati Therapeutics in the 3rd quarter worth $668,000. Finally, Goldman Sachs Group Inc. boosted its stake in Mirati Therapeutics by 845.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 87,858 shares during the period. 64.68% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/12/jamie-christensen-sells-14725-shares-of-mirati-therapeutics-inc-mrtx-stock.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply